A. Loren

发表

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

David L. Porter, Adam Bagg, Wei-Ting Hwang, 2015, Science Translational Medicine.

Fertility issues, fertility preservation, and pregnancy outcome in long‐term survivors

A. Tichelli, A. Loren, A. Rovó, 2021 .

Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant.

M. Pasquini, M. Horowitz, Stephanie J. Lee, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematology and Goliath: Ensuring the Future of Benign Hematology in a World of Combined Hematology-Oncology Fellowships

A. Loren, 2009 .

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

S. Grupp, D. Porter, B. Levine, 2013 .

Post-transplant lymphoproliferative disorder: a review

D. Porter, A. Loren, E. Stadtmauer, 2003, Bone Marrow Transplantation.

Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine.

S. Mineishi, M. Pasquini, R. Gale, 2018, Blood advances.

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.

M. Norkin, H. Nakasone, M. Aljurf, 2018, Blood advances.

Providing personalized prognostic information for adult leukemia survivors.

Alan M. Miller, B. Storer, B. George, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

If All You Have Is a Hammer…: Transplantation for Myelodysplastic Syndrome after Hypomethylating Agents Fail.

A. Loren, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Germline POT1 Variants Can Predispose to Myeloid and Lymphoid Neoplasms

S. Carty, K. Nathanson, A. Bagg, 2021, Leukemia.

Fertility issues in patients with hematologic malignancies.

A. Loren, 2015, Hematology. American Society of Hematology. Education Program.

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

A. Fox, Shrey Sukhadia, J. Morrissette, 2016, Journal of visualized experiments : JoVE.

SP-026 HOW I TREAT ESSENTIAL THROMBOCYTHEMIA

A. Loren, C. Jemison, 2014 .

SP-024 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

D. Porter, B. Levine, C. June, 2014 .

Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents

Shannon R. McCurdy, D. Porter, A. Perl, 2020, American journal of hematology.

Edema with hypoalbuminemia as a rare manifestation of chronic graft versus host disease after allogeneic hematopoietic cell transplant

A. Loren, J. Mangan, M. Denker, 2017, Leukemia & lymphoma.

Incidence, Risk Factors for and Outcomes of Transplant-Associ- ated Thrombotic Microangiopathy

Saber, Marcelo, Edward, 2021 .

Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy

M. Aljurf, M. Pasquini, H. Lazarus, 2020, British journal of haematology.

Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition.

D. Porter, S. Luger, E. Hexner, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation

D. Porter, A. Loren, 2006, Current opinion in oncology.

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation

D. Porter, S. Emerson, A. Perl, 2005, Bone Marrow Transplantation.

Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.

M. Norkin, W. Wood, M. Sorror, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

S. Grupp, D. Porter, B. Levine, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance

J. McQuade, D. Porter, S. Schuster, 2012, Bone Marrow Transplantation.

A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies

A. Loren, R. Banerjee, M. Luskin, 2015, Current Hematologic Malignancy Reports.

Severe Eosinophilia as a Manifestation of Acute Graft-versus-Host Disease

S. Luger, A. Loren, V. Paralkar, 2008, Oncology.

Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).

M. Sorror, J. Wingard, M. Gilleece, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

mpact of Donor and Recipient Sex and Parity n Outcomes of HLA-Identical Sibling Allogeneic ematopoietic Stem Cell Transplantation

D. Porter, A. Cnaan, M. Horowitz, 2006 .

Self-efficacy for Symptom Management in Long-term Adult Hematopoietic Stem Cell Survivors.

H. Jim, J. Wingard, K. Syrjala, 2022, Transplantation and cellular therapy.

Driving Distance and Patient-Reported Outcomes in Hematopoietic Cell Transplantation Survivors

H. Jim, K. Syrjala, Jean C. Yi, 2020, Biology of Blood and Marrow Transplantation.

A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia.

G. Wertheim, P. Gimotty, A. Melnick, 2016, JCI insight.

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment

D. Porter, B. Levine, C. June, 2016, American journal of hematology.

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

Shannon R. McCurdy, M. Carroll, D. Porter, 2022, Blood advances.

Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation

D. Porter, A. Loren, 2008, Bone Marrow Transplantation.

Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Y. Nieto, V. Bhatt, A. El-Jawahri, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Trisomy 8 in an allogeneic stem cell transplant recipient representative of a donor‐derived constitutional abnormality

P. Nowell, D. Porter, S. Luger, 2008, American journal of hematology.

D. Porter, S. Luger, E. Hexner, 2016, American journal of hematology.

Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens

D. Porter, A. Perl, S. Luger, 2013, American journal of hematology.

Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia

Shannon R. McCurdy, D. Porter, K. Pratz, 2022, Leukemia & lymphoma.

Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen.

M. Wasik, A. Loren, M. Luskin, 2014, Clinical lymphoma, myeloma & leukemia.

Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease

D. Porter, A. Perl, S. Luger, 2010, Bone Marrow Transplantation.

Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors.

D. Porter, S. Luger, E. Hexner, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Higher Donor Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Reduced Intensity Allogeneic Transplants with Unrelated Donors

D. Porter, S. Luger, E. Hexner, 2018 .

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

D. Porter, R. Mick, T. Kambayashi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

J. Hoxie, D. Porter, E. Acosta, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Low dose total body irradiation added to fludarabine and busulfan reduced intensity conditioning reduces graft failure in patients with myelofibrosis.

D. Porter, A. Maity, J. Plastaras, 2022, Transplantation and cellular therapy.

Title : " Risk Score for Veno-occlusive Disease After Allogeneic Stem-Cell Transplant "

Marcelo, M. Horowitz, Stephanie J. Lee, 2017 .

Characterization of Pericarditis Following Allogeneic Hematopoietic Cell Transplant.

Shannon R. McCurdy, B. Ky, J. Carver, 2021, Transplantation and cellular therapy.

Clofarabine and busulfan myeloablative conditioning in allogeneic hematopoietic cell transplant for patients with active myeloid malignancies.

Shannon R. McCurdy, D. Porter, K. Pratz, 2022, Transplantation and cellular therapy.

Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation

D. Porter, W. Hwang, T. Miano, 2016, Bone Marrow Transplantation.

Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.

D. Porter, D. Babushok, S. Luger, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies.

M. Aljurf, B. George, M. Flowers, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay.

Shannon R. McCurdy, D. Porter, D. Babushok, 2021, Transplantation and cellular therapy.

Fertility Preservation in Patients with Hematologic Malignancies and Recipients of Hematopoietic Cell Transplants.

A. Loren, S. Senapati, 2019, Blood.

Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T‐cell acute lymphoblastic leukaemia and lymphoma

D. Porter, S. Luger, N. Frey, 2016, British journal of haematology.

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

Gregory M. Chen, F. Bushman, E. Wherry, 2022, Nature.

Clinical guide to fertility preservation in hematopoietic cell transplant recipients

M. Sorror, J. Wingard, J. Pidala, 2014, Bone Marrow Transplantation.

PHYSICIAN PERCEPTIONS AND PRACTICE PATTERNS REGARDING FERTILITY PRESERVATION IN HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS

M. Sorror, J. Wingard, J. Pidala, 2013, Bone Marrow Transplantation.

Hematopoietic Cell Transplantation and Utilization of Fertility Preservation Services.

A. Loren, S. Leppke, T. Hwee, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fluconazole-Induced adrenal insufficiency following allogeneic hematopoietic cell transplant

A. Loren, Craig W. Freyer, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment and Length of Hospitalization in Myeloablative Allogeneic Hematopoietic Transplantation

Shannon R. McCurdy, D. Porter, D. Babushok, 2019, Biology of Blood and Marrow Transplantation.

Leucovorin Following Methotrexate Graft-Vs-Host Disease Prophylaxis in Myeloablative Allogeneic Hematopoietic Transplantation Shortens the Duration of Mucositis and Hospitalization

Shannon R. McCurdy, D. Porter, D. Babushok, 2018, Blood.

Retransplantation of a cardiac allograft inadvertently harvested from a donor with metastatic melanoma.

R. Gorman, L. Schuchter, Shashank S. Desai, 2003, Transplantation.

DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

P. Gimotty, M. Carroll, R. Daber, 2015, Clinical Cancer Research.

DNMT 3 A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia

P. Gimotty, M. Carroll, R. Daber, 2014 .

Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.

M. Sorror, J. Wingard, U. Popat, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation

Shannon R. McCurdy, D. Porter, K. Pratz, 2020, Leukemia & lymphoma.

Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide

Shannon R. McCurdy, D. Porter, K. Pratz, 2022, Leukemia & lymphoma.

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

Alexander Perl, Bruce L Levine, David L Porter, 2006, Blood.

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD 3 / CD 28 costimulation

D. Porter, B. Levine, C. June, 2006 .

A predictive model for the detection of tumor lysis syndrome during AML induction therapy

D. Heitjan, M. Carroll, D. Porter, 2006, Leukemia & lymphoma.

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

S. Grupp, B. Levine, M. Kalos, 2013 .

A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia

M. Carroll, D. Porter, H. Minderman, 2014 .

Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

Tao Wang, Thomas Spitzer, Daniel J Weisdorf, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant

M. Pasquini, B. George, R. Gale, 2019, JAMA pediatrics.

Efficacy of HPA‐1a (PlA1)‐negative platelets in a patient with post‐transfusion purpura

C. Abrams, A. Loren, 2004, American journal of hematology.

High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT

D. Heitjan, D. Porter, S. Luger, 2012, Bone Marrow Transplantation.

Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program.

J. Wingard, D. Stroncek, B. Shaw, 2013, Blood.

Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation.

D. Porter, A. Cnaan, M. Horowitz, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors

Purushottam W. Laud, J. Wingard, K. Syrjala, 2018, Haematologica.

Tocilizumab Is Highly Active for Severe Steroid-Refractory Acute Graft-Versus-Host Disease of the Gastrointestinal Tract

D. Porter, D. Babushok, S. Luger, 2016 .

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hematopoietic Cell Transplantation, Version 2.2020

Y. Nieto, V. Bhatt, A. El-Jawahri, 2020 .

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease

M. Norkin, R. Vij, M. Aljurf, 2013, Leukemia.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

J. Hoxie, D. Heitjan, D. Porter, 2012, The New England journal of medicine.

Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT)

M. Pasquini, U. Popat, Xiaochun Zhu, 2014 .

Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.

A. Gratwohl, J. Passweg, H. Lazarus, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.

A. Loren, Nathan Singh, 2017, Clinics in chest medicine.

Long-term Survival and Late Effects among 1-year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes

Zhiwei, Saber, M. Norkin, 2014 .

Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

D. Porter, R. Mick, S. Luger, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia

Shannon R. McCurdy, D. Porter, K. Pratz, 2021, Blood.

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.

M. Sorror, J. Kurtzberg, S. Mineishi, 2019, Blood.

Late effects of blood and marrow transplantation

A. Loren, R. Banerjee, M. Luskin, 2017, Haematologica.

Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract

D. Porter, D. Babushok, S. Luger, 2019, Bone Marrow Transplantation.

Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.

J. Cortes, M. Aljurf, J. Szer, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

J. Cortes, M. Aljurf, J. Szer, 2013, Blood.

Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation.

W. Wood, M. Horowitz, K. Syrjala, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

with TBI following cyclophosphamide in combination with busulfan compared Better leukemia-free and overall survival in AML in first remission

J. Cortes, M. Aljurf, J. Szer, 2013 .

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

J. Hoxie, D. Heitjan, D. Porter, 2011 .

D. Porter, S. Luger, E. Hexner, 2016, American journal of hematology.

Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL

S. Grupp, D. Porter, B. Levine, 2012 .

Association of Racial/Ethnic and Gender Concordance Between Patients and Physicians With Patient Experience Ratings

J. Shults, N. Mitra, J. Takeshita, 2020, JAMA network open.

Who enrolls in an online cancer survivorship program? Reach of the INSPIRE randomized controlled trial for hematopoietic cell transplantation survivors.

H. Jim, W. Leisenring, Stephanie J. Lee, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Management of relapsed cutaneous T‐Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case

R. Clark, D. Weiner, Ellen J. Kim, 2022, Dermatologic therapy.

Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation.

J. Kurtzberg, C. Martinez, M. Pasquini, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

M. Perales, Richard J. Jones, Y. Efebera, 2022, Blood.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

D. Porter, B. Levine, C. June, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes

M. Pasquini, A. Wickrema, U. Popat, 2016, Haematologica.

Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant

Shannon R. McCurdy, D. Porter, K. Pratz, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

W. Wood, H. Jim, J. Wingard, 2022, Transplantation and cellular therapy.

Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation

A. Alavi, D. Porter, R. Elstrom, 2006, Bone Marrow Transplantation.

Post‐transplant outcomes of induction therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high‐dose melphalan with autologous stem cell support

D. Porter, E. Glatstein, S. Schuster, 2007, American journal of hematology.

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.

D. Margolis, O. Abdel-Wahab, K. Yen, 2012, Blood.

NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.

J. Bolaños-Meade, Y. Nieto, A. El-Jawahri, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study

J. Hoxie, D. Porter, E. Acosta, 2017 .

CLL/SLL diagnosed in an adolescent

G. Wertheim, J. Biegel, L. Kersun, 2014, Pediatric blood & cancer.

Age and gender differences in financial distress among hematopoietic cell transplant survivors

H. Jim, W. Leisenring, Stephanie J. Lee, 2020, Supportive Care in Cancer.

Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation – diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib

A. Bagg, A. Bogusz, E. Ritchie, 2020, Leukemia & lymphoma.

Autologous stem cell transplantation in first complete remission may not extend progression‐free survival in patients with peripheral T cell lymphomas

D. Porter, S. Schuster, A. Mato, 2016, American journal of hematology.

Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes.

D. Porter, N. Mitra, M. Schapira, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stratification of Allogeneic Hematopoietic Cell Transplant Patients by Risk of Developing Veno-Occlusive Disease: A Model for Assigning a Risk Score

Stephanie J. Lee, A. Artz, A. Loren, 2017 .

Contraceptive use and the role of contraceptive counseling in reproductive-aged women with cancer.

S. Domchek, C. Gracia, A. Loren, 2014, Contraception.

mutations and clinical outcome in acute myeloid leukemia Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase

D. Margolis, O. Abdel-Wahab, K. Yen, 2013 .

Title: Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Running Head: 2HG predicts IDH mutations and clinical outcome in AML

Martin, D. Margolis, O. Abdel-Wahab, 2013 .

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.

W. Wood, H. Jim, J. Wingard, 2023, Transplantation and cellular therapy.

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Shannon R. McCurdy, A. Bagg, C. McMahon, 2018, Blood.